Tippapatt/iStock via Getty Images I've owned Hercules Capital ( HTGC ) for quite some time now. But it's not on my shopping list. In fact, I published an article putting it on hold back in June 2025. So I did not buy a single share for nearly a year. I'm happy I did that, because the stock price has declined by almost 8% since then. Seeking Alpha Now, I see that HTGC has just published data for Q1...
Tippapatt/iStock via Getty Images I've owned Hercules Capital ( HTGC ) for quite some time now. But it's not on my shopping list. In fact, I published an article putting it on hold back in June 2025. So I did not buy a single share for nearly a year. I'm happy I did that, because the stock price has declined by almost 8% since then. Seeking Alpha Now, I see that HTGC has just published data for Q1 2026. After almost a year from the last article, I think it's a good time to follow up on HTGC. But I'd like to say right here: I will keep HTGC on hold. I'm not buying more shares. Why? Because I don't like the price. I'm very much impressed by HTGC's portfolio and their approach to underwriting. But the price is too high with a ~37% premium to book value. I think it limits total return potential, and that's why I'm still not buying more shares. HTGC Has a Great Portfolio and Track Record HTGC's internal performance ratings look very well While I see many BDCs struggling with worse internal ratings of their portfolio companies, I don't think that's the case in HTGC. On the contrary, I see a great improvement. In the table below, I see that 4-5-rated investments represent ~0.9% of the portfolio . It was much higher just a year ago (~5%). I was very satisfied to see that. Also, 1-rated investments increased their share in the portfolio, which I also consider a good sign. HTGC's Investor Presentation What's the best summary of improving the credit health of HTGC's portfolio? I see that in the chart above the table. The weighted rating amounted to 2.11 as of Q1 2026. I don't see a better rating through the Q1 2023 - Q1 2026 period. So that's great news to me and other HTGC's shareholders. I think the software risk is well-managed I consider HTGC one of the best BDCs in terms of software experience. It's a very broad sector. I think that some players will be more affected by the AI revolution and some less. What's the key to a more resilient software portfolio? I liked how the...
stockcam GameStop ( GME ) CEO Ryan Cohen’s eBay ( EBAY ) account has been suspended, he said in a post on X. Cohen posted an image with the text “your eBay account has been permanently suspended because of activity that we believe was putting the eBay community at risk”. Cohen, in an interview with the TBPN technology show on Tuesday explained that his plan is to increase earnings per share at eBa...
stockcam GameStop ( GME ) CEO Ryan Cohen’s eBay ( EBAY ) account has been suspended, he said in a post on X. Cohen posted an image with the text “your eBay account has been permanently suspended because of activity that we believe was putting the eBay community at risk”. Cohen, in an interview with the TBPN technology show on Tuesday explained that his plan is to increase earnings per share at eBay ( EBAY ) enough to easily offset any dilution to GameStop ( GME ) shareholders. More on GameStop, eBay eBay: GameStop Bid Doesn't Add Up GameStop's 'Crazy Idea' To Buy EBay Isn't So Crazy, But It Is Risky eBay And GameStop: A Deal Made In Meme Heaven GameStop's Ryan Cohen explains how he would turn around eBay eBay's board to meet this week on GameStop's offer - Semafor
Earnings Call Insights: Sarepta Therapeutics (SRPT) Q1 2026 Management view “We entered 2026 with a clear set of priorities, stabilize the business, restore confidence in growth, maintain financial strength and continue advancing a pipeline with the potential to define Sarepta's next era.” (CEO Douglas Ingram) Sarepta reported marketed product stabilization after 2025 disruption and said its comme...
Earnings Call Insights: Sarepta Therapeutics (SRPT) Q1 2026 Management view “We entered 2026 with a clear set of priorities, stabilize the business, restore confidence in growth, maintain financial strength and continue advancing a pipeline with the potential to define Sarepta's next era.” (CEO Douglas Ingram) Sarepta reported marketed product stabilization after 2025 disruption and said its commercial and educational reset is aimed at returning ELEVIDYS to growth; “we are reiterating our full year guidance of $1.2 billion to $1.4 billion and would counsel prudence in raising estimates prematurely.” (CEO Ingram) The company highlighted its PMO durability and regulatory work to strengthen franchise longevity, with VYONDYS and AMONDYS conversion efforts moving forward; “we have submitted sNDAs seeking to transition those therapies from accelerated approval to traditional approval.” (CEO Ingram) Sarepta emphasized ELEVIDYS evidence and treatment scale; “to date, more than 1,300 patients have been treated with ELEVIDYS across clinical trials and commercial use around the world.” (CEO Ingram) Financial strength and self-funding remained a central message; “we ended the quarter with approximately $748 million in cash and investments… generated positive cash flow, excluding Arrowhead-related payments… It allows us to fund our pipeline without relying on the equity markets.” (CEO Ingram) “On behalf of the Sarepta team, I'm pleased to report a strong quarter of financial execution to start the year, where our base business was profitable and cash flow positive.” (EVP & CFO Ryan Wong) Outlook Sarepta reiterated 2026 net product revenue guidance of $1.2 billion to $1.4 billion, with management repeatedly warning about the long cycle from interest to infusion; “the time from enrollment form to infusion is a 6-month process.” (EVP & Chief Commercial Officer Patrick Moss) Management framed the ELEVIDYS recovery as gradual rather than abrupt; “reestablishing momentum will lead to ...
Earnings Call Insights: OraSure Technologies (OSUR) Q1 2026 Management view "Overall, we continue to advance our strategic transformation and execute with discipline as we focus on driving growth in 2026 and beyond." (President, CEO & Director Carrie Eglinton Manner) "We're also preparing for several near-term catalysts for growth, including our 2 product launches planned for mid-year." (President...
Earnings Call Insights: OraSure Technologies (OSUR) Q1 2026 Management view "Overall, we continue to advance our strategic transformation and execute with discipline as we focus on driving growth in 2026 and beyond." (President, CEO & Director Carrie Eglinton Manner) "We're also preparing for several near-term catalysts for growth, including our 2 product launches planned for mid-year." (President, CEO & Director Carrie Eglinton Manner) "One, our rapid molecular self-test for chlamydia and gonorrhoeae, also known as CT/NG. And two, our Colli-Pee at-home urine collection device for sexually transmitted infections or STIs." (President, CEO & Director Manner) "Looking at our Q1 results, total revenue was $27.9 million, which was above the midpoint of our guidance range, and we generated solid gross margin expansion." (President, CEO & Director Manner) "In our International Diagnostics business, we made significant progress on our initiatives to establish closer relationships with some of our distribution partners in Africa and their in-country value-added assembly and manufacturing, also known as near-shoring." (President, CEO & Director Manner) "During Q1, we delivered on initial orders to one of our near-shoring partners." (President, CEO & Director Manner) "Total revenue in the first quarter was $27.9 million and grew 4% on a sequential basis." (Chief Financial Officer Kenneth McGrath) "Our GAAP gross margin in the first quarter was 42.3%." (Chief Financial Officer McGrath) Outlook "We expect revenue in the second quarter of $27 million to $30 million, which includes a negligible amount of revenue for COVID-19 testing." (Chief Financial Officer Kenneth McGrath) "We expect our gross margin in Q2 to be similar to Q1." (Chief Financial Officer McGrath) "We anticipate our operating expense will be in the high $20 million range in Q2, which includes non-run rate expenses and excludes stock compensation." (Chief Financial Officer McGrath) "Then we expect operating expense...
(RTTNews) - Atmos Energy Corporation (ATO) reported that its second quarter net income increased to $581.9 million from $485.6 million, last year. Diluted net income per share was $3.47 compared to $3.03. Second quarter total operating revenues were $1.96 billion compared to $1.9
(RTTNews) - Atmos Energy Corporation (ATO) reported that its second quarter net income increased to $581.9 million from $485.6 million, last year. Diluted net income per share was $3.47 compared to $3.03. Second quarter total operating revenues were $1.96 billion compared to $1.9
BlackRock Inc. is trying to recoup money it’s owed on a private credit loan in China, setting up a test for how Asia’s burgeoning reputation as a comparatively safer market for such deals will play out in reality. After a unit of Chinese cold-chain logistics provider Metcold defaulted on a $27.5 million portion of a BlackRock loan in early April, the US investment giant has been looking to enforce...
BlackRock Inc. is trying to recoup money it’s owed on a private credit loan in China, setting up a test for how Asia’s burgeoning reputation as a comparatively safer market for such deals will play out in reality. After a unit of Chinese cold-chain logistics provider Metcold defaulted on a $27.5 million portion of a BlackRock loan in early April, the US investment giant has been looking to enforce a personal guarantee from Henry Ha, Metcold’s founder and CEO, people familiar with the matter said, requesting anonymity discussing private matters. The episode, while relatively small, is drawing scrutiny within Asia’s private credit circles as the first default in BlackRock’s Asia Pacific Private Credit Opportunities Fund II. That’s making it one of the most recent tests cases as regional practitioners continue to pitch Asia as a sanctuary from pressures in the $1.8 trillion global asset class, citing more conservative lending practices. BlackRock has other collateral in the loan’s security package, according to documents seen by Bloomberg News. But the money manager has no claims on the operating companies that own the underlying physical assets, according to the people. BlackRock declined to comment. Metcold said the points are factually incorrect and incomplete, without elaborating. BlackRock’s Asia Private Credit Fund Sees China Borrower Default Asia Private Credit Debate Changes to Soothe Jittery Investors Asia Private Credit Chases Gains as Stress Mounts for US Peers Underwriting in Asia tends to be “more disciplined” than in the US, in part out of necessity given that some parts of the region are developing markets with “not very strong legal frameworks,” Neeraj Seth , chief investment officer at hedge fund 3R Investment Management, recently said. The region has also dodged a surge in redemption requests that rocked at least a dozen funds elsewhere recently, in part as it has less exposure to software firms threatened by artificial intelligence. But Asia isn’t en...
Space analytics firm HawkEye 360 ( HAWK ) has priced its initial public offering at $26 per share, raising approximately $416M through the sale of 16M shares of common stock as the company moves to expand its commercial and government intelligence capabilities, it said on Wednesday. The Herndon, Virginia-based firm had targeted a price range of $24 to $26 per share. The final pricing values Hawk...
Space analytics firm HawkEye 360 ( HAWK ) has priced its initial public offering at $26 per share, raising approximately $416M through the sale of 16M shares of common stock as the company moves to expand its commercial and government intelligence capabilities, it said on Wednesday. The Herndon, Virginia-based firm had targeted a price range of $24 to $26 per share. The final pricing values Hawkeye 360 at $2.4B, based on the outstanding shares in its filings. In addition, HawkEye 360 ( HAWK ) has granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of common stock at the initial public offering price. All the shares of common stock are being offered by HawkEye 360. The shares are expected to begin trading on the New York Stock Exchange under the ticker symbol "HAWK" on May 7, 2026. The offering is expected to close on May 8, 2026. Following a robust April for new listings, IPO activity is expected to accelerate in the months ahead, with HawkEye 360 and Suja Life ( SUJA ) poised to gauge investor appetite for defense technology and consumer-focused brands, respectively. More on HawkEye 360, Inc. HawkEye 360 Spies IPO As Revenue Growth Takes Off HawkEye 360 launches IPO roadshow Financial information for HawkEye 360, Inc.